Immunotherapy for ATL using specific chimeric antigen receptor

Research Project

Project/Area Number	25461427
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Research Field	Hematology
Research Institution	Kagoshima University
Principal Investigator	Yoshimitsu Makoto 鹿児島大学, 医歯学域医学系, 准教授 (70404530)
Co-Investigator(Kenkyū-buntansha)	ITOH Yuji 鹿児島大学, 理工学域理学系, 教授 (60223195)
Project Period (FY)	2013-04-01 – 2016-03-31
Project Status	Completed (Fiscal Year 2015)
Budget Amount *help	¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000) Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000) Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000) Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Keywords	CART療法 / T細胞受容体 / CART / TCR / NOJマウス / 成人T細胞白血病リンパ腫 / 免疫不全マウス / 異種移植
Outline of Final Research Achievements	Adult T cell lekukemia/lymphoma is a retractable hematological malignancy, which requires effective therapeutic modality. It is very important for immunotherapy using chimeric antigen receptor T cell to identify therapeutically relevant target antigen. Here we assessed T cell receptor repertoire among patients with ATL. We found that T cell receptor V beta 2 was the most prevalent TCR, more than 15% of ATL patients express TCRVb2. After cloning of TCRVb2 by RACE, we developed TCRVb2 expressing lentiviral vector and establish TCRVb2 highly expressing cell line. We tried to identify anti-TCRVb2 specific antibody by phage display library. Further optimization of this protocol need to be explored.